Complete Conference Coverage Archive
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Researchers identified nearly 80 significantly mutated genes in prostate cancer, including many novel genes and pathways.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
The risk for developing prostate cancer is more than 5 times higher for men in the top 1% of the genetic risk score group.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.
About 4 in 10 partners of young breast cancer survivors experience anxiety.
Three-quarters of patients diagnosed with cancer report decreased physical activity.
There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.
Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).
GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.
Phase 2 trials of investigational agents for pancreatic cancer treatment do not usually progress to phase 3.
Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.
For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.
Salvage therapy with nivolumab was efficacious among patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) cancer.
The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.
Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.
Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.
Despite differences in the safety profiles and rates of adverse events, both FOLFIRI and XELIRI were safe and well-tolerated as second-line therapy.
Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.
Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.
Treatment with nintedanib significantly improved progression-free survival among heavily pretreated patients with metastatic colorectal cancer (mCRC).
Three cycles of epirubicin plus cyclophosphamide (EC) followed by docetaxel (EC-D) offered no survival benefits.
Findings from a preclinical study of PI3K inhibitor taselisib's mechanism of action in mutant cell line and breast cancer xenograft models surprised researchers.
Used alongside clinical variables, molecular prognostic signatures can identify postmenopausal women with ER+, HER2-negative breast cancer.
Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.
BRCA1 and BRCA2 mutation status predicts PFS in carboplatin-treated women with recurrent or metastatic triple-negative breast cancer (TNBC).
An orally-available formulation of proteolysis-targeting chimera (PROTAC) successfully degraded and reduced levels of estrogen-receptor alpha (ERα) protein.
Cancer drug prices will probably continue their steady climb.
Aromatase inhibitor (AI) therapy is associated with endothelial dysfunction, a predictor of cardiovascular disease.
A biological risk profile can identify patients with ductal carcinoma in situ (DCIS) who are at high risk of recurrence and might benefit from radiotherapy.
Physical exercise might modulate the upregulation of immune and inflammatory-pathways involved in breast cancer.
Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).
Subpopulations of tumor cells can form microanatomic associations with endothelial cells and macrophages.
Neoadjuvant therapy with the investigational oral CDK 4/6 inhibitor abemaciclib as monotherapy and with anastrozole reduced Ki67 levels.
Adding the PI3K inhibitor buparlisib to fulvestrant endocrine therapy improves progression-free survival (PFS).
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Circulating tumor microRNA signatures might discriminate between neoadjuvant chemotherapy-responsive and -unresponsive HER2+ breast cancers.
Post-mastectomy radiotherapy is associated with increased rates of complications like hematoma, infection, and reduced patient-reported satisfaction.
Circulating tumor cell (CTC) counts prior to neoadjuvant chemotherapy for early-stage breast cancer predict survival.
Pathologic complete response (pCR) rates in hormone receptor (HR)-positive, HER2-positive breast cancer were unchanged.
PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
BRCA1/2 mutation status does not predict survival among young patients.
Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
Emerging research suggests that tumor development involves much more than mutant clones.
Circulating free tumor DNA techniques might improve the ability to match tumor mutations to genotype-matched targeted therapies.
BARD1, RAD51D, and MSH6 gene variants increase breast cancer risk.
Higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS).
Gene mutation status is prognostic for postmenopausal women with early-stage estrogen receptor-positive (ER+) breast cancer.
Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.
Adding veliparib to carboplatin and paclitaxel for patients with advanced BRCA mutation-associated breast cancer is safe but did not improve survival.
A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).
Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.
Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC
Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).
Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC
First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).
Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control
Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.
The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.
Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).
Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.
Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.
Integration of newer targeted agents into combination therapies will necessitate the development of predictive biomarkers.
Adding everolimus to fulvestrant improves progression-free survival (PFS) among postmenopausal women.
Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).
Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.
The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.
Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.
Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.
Lack of research data and failure to consider patients' functional age affects how older adults with breast cancer are managed.
Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.
Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.
Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.
Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.
A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.
Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.
Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.
Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).
There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease
Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.
All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.
Generic formulations of imatinib appear to be non-inferior to Novartis's Gleevec brand formulation with respect to clinical efficacy and tolerability.
Serum free light chain measurements correlate more closely with clinical outcomes than urine assessments in patients with light chain multiple myeloma.
Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.
Pediatric patients with acute lymphoblastic lymphoma (ALL) at standard risk for relapse do not benefit from lower-intensity, delayed intensification therapy.
Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.
A high percentage of patients with limited-stage small cell lung cancer (SCLC) are elderly, but there is a lack of data concerning the efficacy and safety.
Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).
Researchers described "modest success" in a systematic multi-step clinical program to improve tobacco practices.
Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.
A novel risk-prediction model can identify patients at an increased risk of mortality following surgical treatment.
Researchers discussed efforts to demonstrate that fibroblast growth factor 18 (FGF18) is overexpressed in malignant pleural mesothelioma (MPM) tissues and cell models.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
- Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future
- NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib